Germline Cancer Testing in Unselected Patients With Neuroendocrine Neoplasms: A Multi-center Prospective Study
Oluseyi Abidoye(WinnMed), Mohamad Bassam Sonbol(Mayo Clinic), Margaret Klint(Arizona Department of Health Services), RL Nussbaum(Invitae (United States)), Katie Kunz(Arizona Department of Health Services), Tanios Bekaii‐Saab(AstraZeneca (United Kingdom)), Zaid Elsabbagh(Apple (Israel)), N. Jewel Samadder(WinnMed), Thorvardur Halfdanarson(Mayo Clinic), Jason Starr(Cancer Clinic), Abdullah Alsulaiman(WinnMed), Samee Zane Alheraki(WinnMed), Daniel Ahn(WinnMed), Michael Golafshar(Arizona Department of Health Services), Edward Esplin(Invitae (United States)), Cody Eslinger(WinnMed)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
|The Journal of Clinical Endocrinology & Metabolism|2015|328